Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Aberrant vpr protein | Starlite/ChEMBL | No references |
Homo sapiens | ATPase family, AAA domain containing 5 | Starlite/ChEMBL | No references |
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trichomonas vaginalis | set domain proteins, putative | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Echinococcus multilocularis | atpase aaa+ type core atpase aaa type core | Get druggable targets OG5_139225 | All targets in OG5_139225 |
Onchocerca volvulus | Get druggable targets OG5_131470 | All targets in OG5_131470 | |
Brugia malayi | Pre-SET motif family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | Dual oxidase homolog | 0.2973 | 1 | 1 |
Onchocerca volvulus | 0.0286 | 0.0881 | 0.0881 | |
Plasmodium falciparum | centrin-4 | 0.0027 | 0 | 0.5 |
Echinococcus granulosus | histone lysine methyltransferase setb | 0.0036 | 0.0032 | 0.0532 |
Trypanosoma brucei | ferric reductase transmembrane protein, putative | 0.2213 | 0.7423 | 0.5 |
Echinococcus multilocularis | histone lysine methyltransferase setb histone lysine methyltransferase eggless | 0.0036 | 0.0032 | 0.0099 |
Echinococcus multilocularis | histone lysine N methyltransferase SETMAR | 0.0036 | 0.0032 | 0.0099 |
Toxoplasma gondii | histone lysine methyltransferase SET/SUV39 | 0.0036 | 0.0032 | 1 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.2213 | 0.7423 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0604 | 1 |
Echinococcus multilocularis | atpase aaa+ type core atpase aaa type core | 0.0979 | 0.3234 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.0032 | 0.0032 |
Brugia malayi | Pre-SET motif family protein | 0.0036 | 0.0032 | 0.0032 |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 0.0881 | 1 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.0763 | 0.0763 |
Onchocerca volvulus | 0.0036 | 0.0032 | 0.0032 | |
Brugia malayi | Cytochrome P450 family protein | 0.0057 | 0.0103 | 0.0103 |
Entamoeba histolytica | hypothetical protein | 0.0632 | 0.2055 | 1 |
Echinococcus granulosus | geminin | 0.0205 | 0.0604 | 1 |
Treponema pallidum | hypothetical protein | 0.0632 | 0.2055 | 0.5 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.0763 | 0.0763 |
Plasmodium vivax | SET domain protein, putative | 0.0036 | 0.0032 | 0.5 |
Echinococcus multilocularis | geminin | 0.0205 | 0.0604 | 0.1869 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0604 | 1 |
Echinococcus granulosus | 5'partial|histone lysine N methyltransferase SETDB2 | 0.0035 | 0.0028 | 0.0458 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0057 | 0.0103 | 0.0103 |
Loa Loa (eye worm) | blistered cuticle protein 3 | 0.2973 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0759 | 0.2487 | 0.2487 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.2213 | 0.7423 | 0.5 |
Leishmania major | ferric reductase, putative | 0.2213 | 0.7423 | 0.5 |
Giardia lamblia | Programmed cell death protein-like protein | 0.0027 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.8913 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 4.1078 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493106, AID493143] | ChEMBL. | No reference |
Potency (functional) | 4.1095 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.